- Exact Sciences (EXAS, Financial) launches Oncodetect™, a new molecular residual disease test for multiple solid tumors.
- Oncodetect detects cancer recurrence up to two years earlier than imaging, tracking up to 200 ctDNA variants.
- Potential market of over 3 million eligible American patients; Medicare reimbursement discussions underway.
Exact Sciences Corp. (EXAS) has unveiled Oncodetect™, a cutting-edge molecular residual disease (MRD) test designed for multiple solid tumors, capable of identifying cancer recurrences up to two years sooner than conventional imaging techniques. This innovative test detects up to 200 ctDNA variants, positioning it as one of the most comprehensive MRD tests currently available.
The Oncodetect test can identify a single ctDNA molecule in 20,000 cfDNA molecules, providing clear "Detected" or "Not Detected" results alongside quantitative data. Patients who test positive with Oncodetect are 50 times more likely to experience cancer recurrence, emphasizing its clinical significance. The test's claims are supported by the robust Alpha-CORRECT study, which includes nearly five years of follow-up data on colorectal cancer recurrence.
Exact Sciences is integrating Oncodetect into its ExactNexus platform, partnering it with tests like OncoExTra and Riskguard to create a comprehensive testing ecosystem. With a potential market of over 3 million eligible US patients, the test's success could significantly impact revenue growth. Medicare reimbursement coverage is critical for widespread adoption, and negotiations are actively ongoing.
